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ABSTRACT 
 
Structural Study of Polyglutamine and Molecular Mechanism of  
Toll-Like Receptor Signaling. (December 2008) 
Zhuyun Liu, B.S., Nankai University 
Chair of Advisory Committee: Dr. Pingwei Li 
 
 Huntington’s disease (HD) is caused by the expansion of a CAG repeats 
encoding polyglutamine (polyQ) in the first exon of Huntingtin (Htt) gene. In HD 
patients, polyQ contains 36-183 glutamine residues, whereas normal individuals have a 
polyQ of only 8-35 residues. To elucidate this threshold phenomenon of polyQ 
aggregation, fluorescence proteins CFP and YFP were attached to both ends of polyQ of 
different lengths. FRET (fluorescence resonance energy transfer) was conducted to 
characterize the conformation of polyQ in the pre-aggregation state. Our FRET data 
show that both the normal and expanded polyQ tracts reveal the same extended structure 
in low concentration. Longer polyQ has multiple cooperative binding sites with higher 
avidity. PolyQ tracts form aggregates when proteins exceed a critical concentration. The 
antibody MW1 Fv fragment binds to polyQ, breaks apart polyQ oligomer and stabilizes 
it in a more extended conformation. 
 The addition of polyproline to the C-terminus inhibits polyQ aggregation by 
inducing PPII-like Helix structure. To understand how the flanking sequence affects the 
polyQ structure, the structure of Q10P10 peptide in complex with MW1 Fv was 
 iv
determined by protein crystallography and compared with Q10/Fv crystal structure.  
Q10P10 peptide bound to Fv has a similar extended structure as Q10 peptide when a 
polyproline tract adopts PPII helical structure sticking out of the complex.  
Toll-like receptors are transmembrane receptors on different kinds of leukocytes. 
They can recognize the structural conserved molecular motifs derived from microbes. 
On the upstream of the TLR signal pathway, TLRs recruit the adaptor protein-MyD88 
through TIR/TIR domain interaction, and MyD88 recruits the downstream kinases 
IRAK4 and IRAK1 through death domain/death domain interaction. Pellino1, a newly 
identified E3 ubiquitin ligase, is also involved in TLR signaling by adding polyubiquitin 
chain to IRAK1 in conjugation with Ubc13/Uev1a E2 complex. TIR/TIR and DD/DD 
binding motifs were studied with techniques including mutagenesis, analytical gel 
filtration, NMR spectroscopy and crystallography. We identified a MyD88DD 
(E52QR62S) double-mutant that attenuates protein aggregation without interrupting the 
binding with IRAK4. This double mutant is a good candidate for structure determination 
by NMR spectroscopy. Our ubiquitination assay showed Pellino1 catalyzes 
polyubiquitination in the presence of Ubc13/Uev1a in vitro. Needle cluster-shaped 
crystals of Pellino1/Ubc13/ Uev1a protein complex were obtained by “hanging drop” 
method of vapor diffusion.  Once the crystallization conditions are optimized, we will be 
able to collect X-ray diffraction data for this E2/E3 complex.  
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HD Huntington’s Disease 
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Htt Huntingtin Protein  
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CHAPTER I 
INTRODUCTION 
Structural Study of Polyglutamine 
Huntington’s disease and Huntingtin protein 
Huntington’s disease is a genetic neurological disorder. It results from the 
programmed degeneration of neurons in a certain area of brain (Figure 1).The patients 
show symptoms including uncontrolled movement, slurred speech, depression and loss 
of cognitive function. More than 15,000 Americans have Huntington’s disease, while at 
least another 150,000 have 50 percent risk of developing the disease, and thousands 
more of their relatives live with the possibility of late onset of Huntington’s disease (data 
from NINDS). Currently, there is no cure for Huntington’s disease, but some treatments 
can reduce symptoms and prevent complications.  
Huntington’s disease was first described by the physician George Huntington in 
1872, but the gene associated with the disease was not discovered until 1993 (HDCRG, 
1993). Huntingtin (Htt) gene encodes a 346 kD protein of unknown function. Htt protein 
is widely expressed in human tissue all over the body (Dure et al., 1994), and the 
expression level is the highest in the brain, especially in cerebellum followed by the 
cortex, striatum, hippocampus and olfactory lobe (Landwehrmeyer et al., 1995). In mice, 
deletion of Htt gene causes early embryonic lethality, whereas later null mutation of Htt 
results in neuronal degeneration (Dragatsis et al., 1998; Duyao et al., 1995; Nasir et al., 
1995; Zeitlin et al., 1995). 
Investigations on Htt protein’s exact function have hinted at its role as a scaffold 
protein that interacts with many proteins, including splicesome, transcription complex, 
and signaling proteins (MacDonald et al., 2001; Jones, 2000). The entire 350 kD protein 
have a 36 tandem “α helix-loop-α helix” motif stacking together to form a curvature to 
foster the protein-protein interaction or RNA-protein interaction (MacDonald, 2003). 
Based on localization experiments, Htt protein is predominantly distributed in cytoplasm, 
This thesis follows the style of the Journal of Neuroscience. 
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but it can shuttle between nucleus and the cytoplasm. Therefore it is also likely to 
involve with cytoskeletal function or vesicle transportation (Ross, 2002).  
 
 
 
 
 
 
FIGURE 1. Neuropathology of Huntington's disease in postmortem brain. Brain mass 
loss with the increasing severity of disease (from left to right).  
(http://www.buckinstitute.org/site) 
 
 
 
Polyglutamine pathogenesis 
The first exon of Htt gene contains a repeated CAG region encoding polyQ tract 
(Figure 2). The number of glutamine residues may vary among different individuals. In 
HD patients huntingtin contains 36-183 glutamine residues, whereas the normal 
individuals have a poly Q tract of only 8-35 residues (Rubinsztein et al., 1996; 
Sathasivam et al., 1997). The disease severity and the early onset are closely related to 
the length of the polyQ tract. The children of the HD patient usually suffer from more 
severe symptoms and earlier onset because of the CAG repeat expansion during 
oogenesis and spermatogenesis.  
The molecular mechanism for the correlation between polyQ and the disease 
progression remain unclear. A common feature of neurodegenerative diseases caused by 
polyQ expansion is the formation of inclusion bodies in affected brain regions. Electron 
 3
microscopy images of brain sections reveal that neuronal inclusions of mutant huntingtin 
protein show fibrilla morphology (Scherzinger et al., 1997). Similar neuronal inclusions 
of aggregated protein were observed in other polyglutamine diseases, including SBMA, 
DRPLA and SCA.  
 
 
 
 
 
 
 
FIGURE 2. Amino acid sequence of HD exon 1 with 23 glutamines.  The polyglutamine 
region is highlighted in blue, and the polyproline regions are highlighted in red.  
 
 
 
Here is a widely accepted mechanism for the formation of amyloid fibril from 
elongated polyQ tract (Figure 3). When a polyQ is within the pathological range (>37 
glutamines), the elongated polyQ tract is transformed from a random coil structure into a 
“toxic fold”, which is rich in β-sheet structure. Then dimers, trimers and larger 
oligomers are formed during a lag time. After the protein concentration exceeds a critical 
value, unstable nuclei are slowly forming. Once cross the threshold of nucleation, the 
fibrils formation becomes thermodynamically favorable and leads to rapid grow of 
amyloid fibrils. It is commonly assumed that the expanded poly Q tract with an altered 
protein conformation gives rise to aberrant binding interactions with other cellular 
proteins, such as transcription factors, heat shock proteins, ubiquitin and proteasome 
components, leading to protein aggregation and sequestration.  
However, other studies indicate that protein aggregation is not the main cause of 
cellular toxicity. Conversely, it has been suggested that the aggregates could represent a 
cellular protective response by which the cells try to degrade the toxic expanded protein 
MATLEKLMKA    FESLKSFQQQ   QQQQQQQQQQ 
QQQQQQQQQQ    PPPPPPPPPP   PQLPQPPPQA 
QPLLPQPQPP    PPPPPPPPGP   AVAEEPLHR 
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(Masino and Pastore, 2001).  In order to solve this paradox, a better understanding of the 
structural features of the polyQ tracts will be crucial to unraveling the mechanism of 
polyglutamine pathogenesis.  
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FIGURE 3. Mechanism of protein aggregation from elongated polyQ. Blue, polyQ tract 
(>37 glutamines); black, other amino acid sequence in Htt protein. X, unknown proteins 
such as transcriptional factors, chaperons, proteases. 
 
 
 
Models of polyglutamine tracts in solution 
There are several models to characterize the structural features of polyQ stretches 
in solution by the methods of molecular modeling. It was proposed that long stretches of 
polyQ could form antiparallel β-strands through hydrogen bonds and further assembled 
into β-sheets or β-barrels (Perutz et al., 1993). A slightly different model suggested 
random coil to β-hairpin transition for a poly Q tracts comprising more than 40 
glutamines (Starikov et al., 1999). Lathrop came up with four possible motifs for poly-Q 
repeats: parallel and antiparallel β-sheet, α-helix and π-helix (Lathrop et al., 1998)  
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Experiments were carried out to test these models. The results of CD experiments 
indicate that normal polyQ tracts (Q9-Q17) are in a random coil structure, whereas solid 
phase Fourier-transform infrared spectroscopy showed controversial results (Sharma et 
al., 1999):  polyQ tracts are in a β-sheet structure rather than in a random coil structure. 
Recent experimental data suggested that polyQ peptides may adopt the left-handed 
polyproline II helix structure (Chellgren et al., 2006; Wang et al., 2006).  
 
PolyQ specific antibodies are useful tools for probing the structure of polyQ 
The study of the polyQ structure is hampered by its flexibility and insolubility. 
The crystal structure of bovine ribonuclease A with GQ10G insertion in the hinge loop 
shows that polyQ region is unstructured (Sambashivan et al., 2005). Polyglutamine 
repeats inserted in a dimeric chymotrypsin inhibitor 2 also show disordered structure 
(Chen et al., 1999). The generation of several polyQ specific antibodies, such as MW1, 
1C3, 3B5H10, provides a new way to determine the polyQ structure. Our lab developed 
a strategy to “fix” the flexible polyQ tract by embedding it in the specific antibody MW1 
and solved the crystal structure of Fv-GQ10G complex. The GQ10G peptide lies in a 
diagonal groove of MW1 Fv (Figure 4B). It adopts an extended structure of about 29 Å 
long, while six out of ten glutamine residues adopt polyproline II helical structure and 
three others adopt a β-strand structure (Figure 4A). These observations agree with the 
results from the previous computer modeling, CD and spectroscopic experiments (Li et 
al., 2007). 
Although crystallography studies of polyQ in complex with MW1 represent a 
feasible approach to probe the structure of soluble polyQ, it also raises the questions: 
Does the structure of the bound polyQ really reflect the structural features of free polyQ 
in solution? Or MW1 induces the conformation change of free polyQ via hydrogen 
bonds and van der waals interactions to fit the polyQ tract into its preexisting groove? 
New approaches should be applied to monitor the conformation change of the polyQ 
tract upon the binding of MW1 Fv.  
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FIGURE 4. Structure of polyQ10 peptide bound to MW1 Fv. (A) The GQ10G peptide 
model superimposed on a 1.68 Å annealed omit electron density map contoured at 0.9 σ. 
(B) Stereo surface representation of polyQ10 peptide binding site in MW1 Fv. Peptide is 
shown in blue stick model (from Li et al., 2007). 
 
 
 
Linear lattice model of polyQ 
The antibody MW1 we used was generated by Paul Patterson in California 
Institute of Technology. Epitope Mapping shows MW1 binds specifically with polyQ 
tract in Htt exon1. It is clear that MW1 bind the expanded polyQ (>36 glutamines) form 
of Htt far more strongly than normal Htt. A widely accepted paradigm to explain this 
phenomenon is that the expanded polyglutamine repeats undergo conformational 
changes and thus preferentially bind with MW1 antibodies. A recent solution NMR 
study of polyglutamine tracts in GST fusion protein by Masino et al. challenged this 
paradigm. They claimed that both the normal polyQ tract (22Q) and expanded polyQ 
tracts (41Q) adopt a random coil structure and no differences were observed between 
GST-Q22 and GST-41Q in NMR spectra.  
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 A new linear lattice model was proposed by Bennet et al. to explain the paradox 
between preferential targeting of expanded polyQ tracts by MW1 and the same random 
coil structure in normal and expanded polyQ tracts (Figure 5). In this model, 
polyglutamine is a linear array of n repeating units. A monovalent MW1 binds to 9 
glutamine residues. A multivalent antibody can bind with a longer polyQ by interacting 
with two or more binding sites simultaneously. The positive cooperativity of the multiple 
binding sites significantly increases the binding affinity. The pathological threshold 
observed in HD is not related to a global conformation change from a soluble, random 
coil structure of polyQ tract to a pathological conformation. Instead, the increased 
number of binding sites of polyQ tract gives rise to the high binding affinity and cause 
the aberrant interaction with other proteins, leading to their functional dysregulation. It 
will be interesting to test this linear lattice model: whether the expanded polyQ tract 
adopt an extended conformation similar to short polyQ peptide or a conformation change 
occurs in polyQ above the pathological threshold of 36 glutamines.  
 
 
 
 
FIGURE 5. Linear lattice model for polyQ. PolyQ is a linear array of n repeating units 
(red dots), which adopts an extended structure accessible by multiple copies of ligand. A 
multivalent ligand can bind with high avidity by interacting with two of more binding 
sites simultaneously, thus distinguishing normal and pathologic polyQ (from Bennet et 
al., 2002). 
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Flanking polyproline sequence changes polyQ conformation   
While the work on the structure of polyQ tract is still in progress, recent research 
started to focus on the protein context of polyQ repeats, especially its flanking regions. 
HD exon1 carries a sequence encoding for the human polyproline tract that lies adjacent 
to polyglutamine tract in Huntingtin. Polyproline motifs are responsible for Huntingtin 
interaction with SH3- and WW-domain-containing proteins, such as epidermal growth 
factor receptor (Liu et al., 1997), vesicle trafficking proteins (Qin et al., 2004), 
splicesome and transcriptional factors (Faber et al., 1998; Passani et al., 2000; Sittler et 
al., 1998), and they may be important to fully understand the interaction of mutant 
huntingtin with various proteins. Furthermore, the polyproline region is likely to confer 
structural stability to the Htt exon1. Wetzel and colleagues found that the flanking 
polyproline can suppress mutant Htt fibril formation when it is attached to the C-
terminal of polyQ tract (Bhattacharyya et al., 2006). Based on CD, EM and x-ray 
diffraction, Merdith and colleagues suggested the flanking polyproline sequence 
increases the threshold for polyQ aggregation and inhibits amyloid formation by 
inducing polyproline II like helical structure (Darnell et al., 2007).  
More and more evidence show that the flanking polyproline has great influence 
in polyQ stability and structure. It is the driving force for us to study Q10P10 peptides. 
We speculated that the polyproline region might affect Q10 structure and even its 
binding with Fv.  
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Molecular Mechanism of TLR Signaling 
Pathogen recognition and innate immunity  
Human host are constantly exposed to the attacks of microorganisms in the 
environment. To survive the challenges, hosts have evolved protected systems to 
eliminate the invaded pathogens in the body. Human immune system consists of two 
major subdivisions: innate immunity and adaptive immunity. Innate immunity is the 
second line of defense after the pathogen cross the first line of surface barrier like skin 
and intestinal epithelia. Unlike adaptive immunity, which is based on clonal selection 
from a huge pool of lymphocytes bearing antigen-specific cell surface receptors, the 
innate immune system distinguish self and non-self by  recognizing  certain conserved 
molecular patterns of the microbial pathogens through limited number of germline-
encoded pattern-recognition receptors (PRRs). Three families of PRRs have been 
described: Toll-like receptor (TLR) family, NOD-like receptors (NLRs) and RIG-like 
helicases (RLHs) (Akira et al., 2006; Meylan et al., 2006). Recognition of pathogen by 
these PRRs would leads to activation of signaling cascades involved in immune and 
inflammatory response.  
 
TLR family and their ligands 
TLR family is the first family of PRRs that is studied in detail. TLRs are integral 
membrane protein, which consist of the extracellular domain and the cytoplasmic 
domain. The extracellular domains are responsible for pathogen recognition and contain 
leucine-rich repeats, which usually form a horseshoe structure. The cytoplasmic domain 
shows high similarity to the cytoplasmic portion of the IL-1 receptor and was termed 
TIR domain. So far, 12 members of TLRs have been identified in mammals (Akira et al., 
2006; Meylan et al., 2006; Takeda and Akira, 2005). TLR2 recognizes peptidoglycan in 
Gram-positive bacteria, while TLR4 recognizes lipopolysaccharide (LPS), which is a 
major component of Gram-negative bacterial cell wall (Takeuchi et al., 1999). TLR2 
dimerizes with TLR1 or TLR6 respectively to discriminate the subtle difference between 
diacyl lipopeptides and triacyl lipopeptides. TLR3, TLR7 and TLR9 are located on the 
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endosome surface and responsible for the recognition of viral double stranded RNA, 
single stranded RNA and bacterial CpG DNA respectively (Alexopoulou et al., 2001;  
Heil et al., 2004; Hemmi et al., 2000). TLR5 have shown to be able to detect flagellin 
and mediate immune response to bacteria flagella (Hayashi et al., 2001) (Figure 6). 
 
 
 
TLR1 TLR2
Triacyl
Lipopeptides
TLR2 TLR6
Diacyl
Lipopeptides
TLR4 TLR5
Diacyl
Lipopeptides Flagellin
TLR3
TLR7
TLR9
endosome
dsRNA
ssRNA
CpGDNA
cytoplasmic
extracellular
 
 
 
 
FIGURE 6. TLRs and their ligands (adapted from Takeda et al., 2005). 
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TLR signaling 
Stimulation of TLRs by microbial pathogen activates signal cascades which 
involve the activation of transcription factor NF-κB and interferon regulatory factors 
IRF3, IRF5 and IRF7, resulting in the induction of proinflammatory cytokine genes 
(Akira et al., 2006). Many studies have been done in the recent year to elucidate the 
molecular mechanism by which TLRs trigger the signaling pathway.  
TLRs and IL-1R share a similar intracellular signaling pathway in general. After 
ligand binding, TLRs dimerize and bring their cytoplasmic TIR domains to close 
proximity, which is important for the recruitment of adaptor protein MyD88 (Jin et al., 
2007; Saitoh et al., 2004). MyD88 associates with TLRs through homotypic interaction 
of TIR domains and recruit the following IRAK4 (IL-1R-associated kinase 4) and 
IRAK-1 through homotypic interaction of death domain. IRAK4 phosphorylates IRAK1. 
Phosphorylated IRAK1 recruits TNFR-associated factor 6 (TRAF6) and subsequently 
form a complex of IRAKs, TRAF6 and Pellino1 (Schauvliege et al., 2007).  TRAF6 acts 
as K63-linked E3 ubiquitin ligase and catalyzes polyubiquitination on itself in the 
presence of E2 ubiquitin-conjugating enzyme complex Ubc13/Uev1a (Deng et al., 2000). 
Then TRAF6 recruits and activates a complex containing TGF-β-activated kinase1 
(TAK1) and the TAK1 binding proteins, TAB1 and TAB2. Activated TAK1 complex 
catalyzes the phosphorylation of IKK-β or activates MAP kinase cascade, resulting in 
the activation of NF-κB or AP-1 respectively (Wang et al., 2001). Pellino1 is a novel E3 
ubiquitin ligase that induces K63-linked polyubiquitination of IRAK1 and thus degrades 
IRAK-1 by an unknown mechanism. This suggests that Pellino1 play an important role 
in down regulation of TLR signaling (Ordureau et al., 2008). (See Figure 7)   
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 FIGURE 7.TLR/IL1-R signaling pathway.  
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MyD88 recruitment to TLRs 
There are five human TIR-domain-containing adaptors: MyD88, TIRAP, TRIF, 
TRAM and SARM. Different TLRs use different combination of adaptors. MyD88 is a 
universal adaptor protein for TLRs signaling (O’Neill and Bowie, 2007). MyD88 was 
initially found in myeloid tissues and involved in the terminal differentiation of myeloid 
precursors induced by IL-6. MyD88 was first identified as adaptor protein in TLR 
signaling (Muzio et al., 1997; Wesche et al., 1997).  Later MyD88’s function in TLR 
signaling was further confirmed by studying MyD88 deficient mouse model (Kawai et 
al., 1999; Takeuchi et al., 2000). These mice do not show normal immune response upon 
the stimulation of ligands for TLR2, TLR4, TLR5, TLR7 and TLR9.  
Human MyD88 encodes for a protein of 296 residues, containing an N-terminal 
death domain (DD, 1-110), a C-terminal TIR domain (155-296) and a short linker 
segment named as intermediate domain (ID, 110-155).  MyD88 is recruited to TLRs via 
homotypic interaction of TIR domains. On the basis of protein sequence alignment, 
MyD88 TIR domain has 50 % similarity with TLR1 and TLR2 TIR domains (Figure 8). 
The canonical structure of TIR domain consists of five β-strands forming the core that is 
surrounded by five α-helices on both sides and five loops that connect between each β-
strand and α-helix (Figure 9). Two conserved loops (BB loop and DD loop) are required 
for TIR dimerization between TLR1 and TLR2. BB loop of MyD88 has been shown to 
interfere with the interaction between MyD88 and IL-1R based on the docking model (Li 
et al., 2005), while the DD loop of MyD88 is responsible for the interaction between 
MyD88 and TLR2 (Xu et al., 2000; Dunne et al., 2003). This implicates that MyD88 
might use distinct binding surfaces for different TLRs. Structural studies on the complex 
between MyD88 TIR and TLR TIR would be helpful to clarify this question.  
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BAD AVG GOOD 
 
TLR1    NIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLEKE--GMQICLHERNFVPG 
TLR2    ----------ICYDAFVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPG 
MyD88   --PLGHMP--ERFDAFICYCPSDIQFVQ-EMIRQLEQTNYRLKLCVSDRDVLPG 
cons                :.**:.*.  *  :*:  :: :**:    :::*: .*:.:** 
 
TLR1    KSIVENIITCIEKSY-KSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILI 
TLR2    KWIIDNIIDSIEKSH-KTVFVLSENFVKSEWSKYELDFSHFRLFDENNDAAILI 
MyD88   TCVWSIASELIEKRCRRMVVVVSDDYLQSKECDFQTKFALSL--S---PGAHQK 
cons    . : .     ***   : :.*:* ::::*: ..::  *:          .     
 
TLR1    LLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKLTEQ 
TLR2    LLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRAAIK------ 
MyD88   RLIPIKYKAMKKEFPSILRFITV---CDYT-NPCTKSWFWTRLAKALSL----- 
cons     * **   :: . : .:  ::      ::. : . :  **..*  *:.       
 
 
FIGURE 8. Sequence alignment of MyD88, TLR1 and TLR2 TIR domain. T-COFFEE. 
(Version 6.07) Score=83. 
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FIGURE 9. Crystal structure of TLR1 TIR domain (PDB ID: 1fyv).  
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MyD88 oligomerization  
After MyD88 associates with TLR, this adaptor undergoes oligomerization to 
form a platform for the recruitment of downstream signal molecules. Over expression of 
MyD88 in HEK293 cells increases its oligomerization and results in robust NF-κB 
activation. Mutagenesis studies show that Box2 and Box3 of TIR domain constitute the 
interactive sites for MyD88 oligomerization (Li et al., 2005).  Whether the death domain 
of MyD88 is involved in self-oligomerization remains unknown.  
MyD88 brings IRAK1 and IRAK4 in close proximity and induces 
phosphorylation. MyD88 is the only adaptor in the TLR signal pathway that contains a 
death domain (DD). MyD88 recruits IRAK1 and IRAK4, which also have DD at the N-
terminal through DD/DD interaction.  The death domains play an important role in 
protein assembly in the NF-κB signal pathway, because they can activate their effectors 
via proximity- induced autoactivation, like trans-phophorylation in this case. To date, six 
structures of DD are solved with NMR spectroscopy or X-ray crystallography. All of 
them reveal a common feature of DD superfamily-the six-helical bundle structure with 
variation in length and orientation of the helices (Park et al., 2007a). Despites its 
significant biological function, only one DD/DD complex structure is available, which is 
Pelle-DD/Tube-DD in Drosophila. Pelle is homologous to IRAK4, but Tube has no 
counterpart in mammals. The crystal structure of the complex shows that the C-terminal 
tail of Tube fits within a groove of Pelle, suggesting a “Head to Tail” interface model 
(Xiao et al., 1999). (See Figure 10) In comparison, the death domain of IRAK4 shows a 
protruding loop in the groove, so a steric clash would happen if IRAK4DD and 
MyD88DD adopt the same “head to tail” interaction (Lasker et al., 2005). Either 
IRAK4DD has a different interface for MyD88DD, or IRAK4DD undergoes 
conformational changes to avoid the steric clash.   
All these questions drive us to attempt to crystallize MyD88/IRAK4DD complex. 
A crystal structure of MyD88DD/IRAK4DD complex would shed light on DD/DD 
recruitment mechanism.  
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FIGURE 10. DD-DD complex structure (adapted from Lasker, M et al., 2005). 
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Ubiquitination in TLR/IL-1R  
In addition to the roles TLRs play in innate immunity, they have also been 
characterized in dysregulated inflammation diseases. It is like a two edges weapon that 
you can use to protest yourself from microbial attack and also hurt yourself if it is used 
improperly. There must be a delicate molecular mechanism to turn TLR signaling on and 
off precisely.  
Ubiquitination and de-ubiquitination of TLR network proteins were proposed to 
modulate TLRs signaling in accordance with the needs of host defenses (Lowe et al., 
2006). For example, auto-polyubiquitination of TRAF6 allows for interaction with 
TAK1-TAB2 complex through binding of K63- linked polyubiquitin chain to the zinc 
finger domain of TAB2 and promote TAK1 auto-phosphorylation. Lately a new family 
of E3 ubiquitin ligase-Pellinos was found to involve in TLR signaling (Schauvliege et al., 
2006).  
In ubiquitination, target protein is covalently linked to one or more ubiquitin 
monomers. There are two common ubiquitin attachments: K48-linked and K63-linked. 
K48-linked polyubiquitin chain signals its substrate to 26S proteasome for destruction, 
while K63-linked polyubiquitin chain induces protein-protein interaction for DNA repair, 
endocytosis, and the stress response (Pickart et al., 2000). Both kinds of ubiquitin 
modification are catalyzed through the sequential action of three enzymes: E1 ubiquitin-
activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin-protein ligase 
(Scheffener et al., 1995).   
First, ubiquitin is activated by ATP and forms ubiquitin-adenylate intermediate. 
Then ubiquitin is transferred to E1 by forming a thioester linkage between the C-
terminal carboxyl group of ubiquitin and E1 active site cysteine residue. Next, ubiquitin 
is transfer from E1 to the active site cysteine of E2.  The final step is to convert ubiquitin 
chain from E2 to substrate with the assistance of E3. E3 enzymes are capable of 
interaction with both E2 and protein substrate and acts as the substrate recognition 
modules. (See Figure 11) 
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FIGURE 11. Mechanism of ubiquitination.  
 
 
 
Pellino1 is E3 ubiquitin ligase 
Pellino proteins had been proposed to function as scaffold proteins in TLRs 
signaling, because they bind with multiple proteins including TRAF6, IRAK1, IRAK4 
and TAK1. Pellinos could be RING E3 ubiquitin ligase based on their primary sequence 
alignment (Schauvliege et al., 2006).  All Pellino proteins contain an evolutionary 
conserved RING like domain at the C-terminal, which facilitates the direct transfer of 
ubiquitin from E2 to the target substrate (Figure 12). siRNA knock down of Pellino1 
impaired IL-1 induced NF-κB activation.  
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FIGURE 12. Schematic alignment of some representative Pellino proteins. Different 
exons of a particular Pellino are colored differently, and homologous exons in various 
Pellino sequences are marked in the same color. The RING domain in the C-terminus is 
indicated. (h)=human; (d) =Drosophila.  
 
 
 
Recent publication have confirmed Pellino1 as E3 ligase (Ordureau et al., 2008). 
In vitro polyubiquitination experiments show that Pellino1, together with E2 conjugating 
complex Ubc13/Uev1a induce the formation of K63-linked polyubiquitination of IRAK1. 
K63-pUb-IRAK1 triggers downstream signaling events with unknown mechanism. It 
was proposed that K63-pUb-IRAK1 interact with NEMO-regulatory subunit of the IKK 
complex (NEMO has been shown to be capable of binding pUb chain specifically) and 
contribute to the activation of IKK β and NF-κB.  Pellino1 in combination with another 
E2 conjugating enzyme UbcH3 catalyzes the formation of K48 pUb chains. We propose 
Pellino1 modulates the TLRs signaling by forming either K48 or K63 pUb linkage on 
IRAK1 in presence of different E2 ubiquitin conjugating enzymes. K48 linkage leads to 
IRAK1 degradation and switches off the TLR signaling pathway, while K63 linkage 
targets IRAK1 to IKK β complex and actives NF-κB. IRAK1 promotes reciprocal 
polyubiquitination of Pellino1 and leads to the degradation of Pellino1. It reveals a 
bidirectional regulation between IRAK and Pellino protein and suggests a novel 
mechanism for TLRs signal modulation.  
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E3 ubiquitin ligase contains a 70 residue RING finger bearing a set of cysteines 
and histidines which coordinate with two zinc atoms. RING domain mediates the 
interaction with the appropriate E2 enzyme and facilitates the direct transfer of ubiquitin 
from E2 to substrate (Pickart et al., 2001). Our lab determined the structure of Pellino1 
and it shows that Pellino1 contains two CHC2 RING motifs and each of the two RING 
motifs binds one zinc atom. Docking of RING domain like of CHIP U-box to the 
structure of Pellino-1 shows that it is likely that first RING domain of Pellino-1 is 
involved in E2 binding. The second RING domain function remains unclear. This 
tandem arrangement of two RING motifs differs from all other known RING ubiquitin 
ligases, which generally contain a C3HC4 motif to coordinate with two zinc atoms. 
Compared with CHIP-UBC13-Uev1a complex and c-Cbl-Ubch7 complex, Pellino1 
should adapt a different interaction motif with E2 (Zhang et al., 2005; Zheng et al., 
2000). A crystal structure of E2/E3 complex will give us new insight into the mechanism 
of Pellino1 ubiquitination. 
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CHAPTER II  
STRUCTURAL STUDY OF POLYGLUTAMINE 
Objective 
The importance of this polyglutamine tract is with no doubt, and lots of efforts 
have been exerted to understand how polyQ in the N-terminal of Huntingtin protein 
leads to pathologenesis in brain. The present study was inspired by the controversial 
models of polyQ raised by different research groups in the past decades. We studied the 
conformational differences between the normal and pathologic polyQ tracts in the pre-
aggregation state. The structural changes that may occur after the addition of flanking 
polyproline were also investigated. Accordingly, we can reformulate the above objective 
to the following specific aims.  
 
Specific aim 1: Testing the linear lattice model of polyQ 
To test this model, we constructed a series of pET28 CFP (Cyan Fluorescence 
Protein) -Qn-YFP (Yellow Fluorescence Protein) expression vectors (n=10, 20, 37, 46) 
and measured the fluorescence intensity of CFP and YFP. FRET efficiencies and the 
distances between CFY and YFP were calculated. Data were analyzed to compare the 
conformation of normal and pathologic polyQ.  
 
Specific aim 2: Monitoring the conformational change of polyQ upon binding of 
MW1 Fv 
To resolve this issue, we monitored polyQ conformation change upon binding of 
MW1 Fv with FRET. Due to the high insolubility of pure polyQ stretches in aqueous 
solvents, in the previous studies, the peptides have been flanked by charged residues, or 
have been studied under extreme and non-physiological condition, such as low pH or 
organic solvents. Here we attached CFP to the N-terminus of the polyQ peptides and 
YFP to the C-terminus. If there is conformational change upon the binding of Fv, FRET 
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efficiency would change correspondingly. Our system has the advantages of studying the 
peptide in protein context and preventing the peptide from aggregation. 
 
Specific aim 3:  Probing the molecular structure of Q10P10 with antibody 
We postulated that the flanking polyproline would affect the structure of polyQ 
tract by inducing PPII helix like structure. To gain further insight into the molecular 
structure of Q10P10 peptide, we crystallized Q10P10 peptide in complex with MW1 Fv 
and solved the structure by molecular replacement. Previous structure of polyQ was 
studied using GQ10G peptide, and thus did not take into account the possible effects of 
the flanking region on the physical properties of polyQ stretches. This study will 
advance our understanding about the pathologenesis of CAG expansion diseases and 
provide an alternative approach for potential drug design.  
 
Experimental Procedures 
Prepare CFP-X-YFP expression vectors 
pECFP-C1 and pEYFP-C1 vectors are gifts from Dr. Chapman, University of 
Wisconsin. DNA primers were ordered from Integrated DNA Technologies (IDT). 
Primers were dissolved in ddH2O to make a final concentration of 1 mg/ml. A typical 
PCR reaction was conducted using platinum Pfx kit (Invitrogen): 1 ul Pfx DNA 
polymerase, 1 ul each primer (1 mg/ml), 50 ng template, 2 ul MgSO4 (50 mM), 5 ul 10x 
buffer, 5 ul 10x enhancer, 1 ul dNTP (25 mM), ddH2O to adjust to a total volume of 50 
ul. The thermal cycle conditions are as follows: initial heating to 95 °C for 2 min, then 
26 cycles of denaturing at 95 °C for 30 sec, annealing at 54 °C for 30 sec and elongation 
at 68 °C (1 kb per min), followed by cooling at 4 °C.  
PCR products were confirmed by agarose gel electrophoresis and purified with 
PCR product purification kit (Qiagen, CA). Double restriction enzyme digestions were 
carried out for both the inserts and vectors as follows: 50 U each restriction enzyme 
(NEB), 5 ul 10x buffer, 100 ng vector or 300-1000 ng insert, ddH2O to final volume of 
50 ul, 37 °C for 5 hrs. Digested products were purified by agarose gel electrophoresis 
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and gel purification kit (Qiagen, CA). Ligation was carried out at room temperature for 
2 hrs with 4 ul insert (40-100 ng/ul), 4 ul vector(15-60 ng/ul) and 1 ul T4 ligase and 2 ul 
10x ligase buffer (Invitrogen, CA). 
CFP was inserted between NdeI and BamHI in pET28 vector, while YFP was 
inserted between HindIII and XhoI, resulting in pET28-CFP-YFP vector. Huntingtin 
exon 1 contains 16Q, 25Q, 37Q, 46Q were inserted into pET28-CFP-YFP vector using 
BamHI and HindIII sites. pET28-CFP-Qn-YFP (n=10, 20, 37, 46) and pET28-CFP-
Q10P10-YFP were generated by primer walking to add 10 residues of glutamine or 
proline at a time. A stop codon was added at the C-terminal of YFP. All the expression 
vectors have been confirmed by sequencing (Institute of plant genomics and 
biotechnology, Texas A&M). 
 
E.coli protein expression test 
pET28 expression vector containing proteins of interest were transformed into 
BL21 for protein expression. One colony was picked from the agar plate and inoculated 
to 3 ml LB media with antibiotics in Falcon tube. It was incubated for 2-3 hr at 37°C by 
shaking at 250 rpm until OD600 reached 0.8. Cell culture was split into 3 x 1 ml LB: 1 ml 
saved as glycerol stock cells at -80°C, 1 ml with 0.8 mM IPTG added for expression test, 
1 ml without IPTG as negative control. The last two were incubated for another 2 hours 
at 37°C and then harvested by centrifugation at 13,000 rpm for 1 min. Cell pellets were 
resuspended in 50 ul lysozyme buffer (0.2 mg/ml) and 1 ul DNase (1 mg/ml). Cells were 
lysed by 4 cycles of freezing in liquid N2 and thawing at 37°C.  Then cell lysate was 
spinned at 13,000 rpm for 2 min. Both supernatant and pellet were loaded on SDS-
PAGE to check protein expression and solubility.  
 
E.coli system protein large scale expression and purification 
50 ul glycerol stock cell was inoculated to 50 ml LB media with antibiotics and 
incubated until OD =1.0.  10 ml of start culture was transferred to each 1 L LB medium, 
and 0.6 mM IPTG was added when OD=0.8. Cell culture was shaken at 37 °C for 3 hrs. 
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Cells were spinned down at 6000 rpm for 10 min. Cell pellets were resuspended with 
Sonic Dismembrator (Model 500, Fisher Scientific) in 200 ml pre-chilled Tris-NaCl 
buffer (150 mM NaCl, 20 mM Tris, pH 7.5). Cell lysate was subjected to sonication 
again after adding 50 ul lysozyme buffer (50 mg/ml). Cell lysate sit on ice for 30 min, 
then was centrifuged down at 10,000 rpm for 15 min. Supernatant was further 
centrifuged at 16,000 rpm for 20 min at 4 °C to remove pellet completely. Supernatant 
was collected for Ni2+ column purification.  
 
Ni2+ affinity chromatography and gel filtration chromatography  
Cell lysate was mixed with Ni-NTA beads for 1 hr at 4 °C. Ni-NTA beads were 
spinned down at 4000 rpm for 2min and washed with wash buffer (10 mM imidazole, 
150 mM NaCl, 20 mM Tris-HCl, pH 7.5) for 3 times. Protein was eluted with elution 
buffer (250 mM imidazole, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5). Thrombin 
cleavage was conducted to cut off His-tag. Then protein sample was concentrated to 2 
ml and loaded on Superdex 200/120ml column to remove His-tag.  
 
Fv expression and purification 
To generate a noncovalent MW1 Fv, the genes encoding the VL domain and the 
VH domain were subcloned into pET22b (+) (Novagen; San Diego, California, United 
States). pET22-VL and pET22-VH were transformed into BL21 and stored in 20% 
glycerol in -80 °C. VL and VH were expressed in 4 L and 2 L LB media separately at 
37 °C for 4 hrs. Cells were harvested and resuspended in 200 ml pre-chilled lysis buffer 
(20 mM Tris, 100 mM NaCl, 5 mM EDTA, 0.5% Triton-X 100, pH 8.0). Cell lysate was 
subjected to sonication (60% amplitude) for 5 min to fully resuspend the cell pellets. 50 
ul lysozyme buffer (50 mg/ml) and 50 ul Dnase buffer (10 mg/ml) were added into cell 
lysate and incubated at room temperature for 30 min for Dnase to digest genomic DNA. 
Inclusion bodies were spinned down at 8000 rpm for 10 min and resuspended in lysis 
buffer again by sonication of 2 min at 60% amplitude. This step was repeated 4 times to 
remove any impurity. Inclusion bodies were washed with 200 ml water to remove 
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detergent and centrifuged down again. Inclusion body pellets weighted about 0.8 g and 
were resuspended in 5 ml water by 20% amplitude sonication for 2 min. 7 M guanidine 
was added to denature the inclusion body. 20 mM GSH was supplemented to reduce the 
disulfide bond. The denatured proteins were centrifuged to remove aggregate protein. 
MW1 Fv was produced by the refolding the VH and VL inclusion bodies together at a 
molar ratio of 1:1 in 2 L refolding buffer (0.1 M Tris, 0.4 M arginine, 5 mM GSH and 
0.5 mM GSSG). Several injections were made in two days to allow the slow refolding 
process of Fv protein. The refolding buffer was concentrated to 5 ml and exchanged to 
running buffer (50 mM Tris, 150 mM NaCl, pH 7.5). The refolded Fv fragment was 
purified by size exclusion chromatography (GE Healthcare, Piscataway, NJ, United 
States) and Ni-NTA chromatography as described before. The final yield of purified Fv 
was ~15 mg/L. 
 
Fluorescence resonance energy transfer 
Fluorescence Resonance Energy Transfer (FRET) is a one of the most useful 
techniques in monitoring conformational change of proteins. FRET takes place when a 
donor fluorophore in an electronically excited state transfers its excitation energy to a 
nearby acceptor fluorophore through resonance interaction. Resonance energy transfer is 
a non-radioactive quantum mechanical process that does not require a collision and does 
not involve production of heat. When energy transfer occurs, the acceptor molecule 
quenches the donor molecule fluorescence, and increases fluorescence emission of the 
acceptor. The phenomenon can be observed by exciting the protein containing both 
donor and acceptor molecules with light of wavelengths corresponding to the absorption 
maximum of the donor fluorophore, and detecting light emitted at wavelengths centered 
near the emission maximum of the donor and acceptor. An alternative detection method, 
growing rapidly in popularity, is to measure the fluorescence lifetime of the donor 
fluorophore in the presence and absence of the acceptor. 
There are several criteria to be satisfied for FRET to happen. 1) The donor and 
acceptor must be within 10-100 Å of each other. 2) An appreciable overlap of the 
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emission spectrum of the donor with the absorption spectrum of the acceptor. 3) 
Fluorescence lifetime of the donor molecule must be of sufficient duration to permit the 
event to occur. The distance dependence of the resonance energy transfer process is the 
primary basis for its utility in investigation of conformational changes.  
              
Fluorescence measurement 
In general, we used 100, 200, 300 nM CFP-Qn-YFP fusion protein in a total 
volume of 1 ml Tris buffer (150 mM NaCl, 50 mM Tris, pH7.5). The emission spectra 
from 450-600 nm were scanned using Perkin Elmer LS 50 Spectrofluorimeter 
(Wellesley, MA). For each spectrum, sample was excited 3 times at 434 nm and scanned 
at 30-sec intervals.  Protein concentrations were calculated based on the Trp absorption 
maximum at 280 nm (A280) and extinction coefficient (ε280): CFP-YFP fusion protein: 
49530 M-1cm-1, CFP: 26025 M-1cm-1, YFP: 23505  M-1cm-1 
 
Calculation of donor and acceptor apparent distance 
Experimental data were analyzed using the Förster equation (Förster, 1948), 
which relates energy transfer efficiency (E) with distance (R) between donor and 
acceptor: 
                                    R6=R06(E-1-1)                                Eq.1 
Where Ro, the Förster distance (in Å) at which the transfer efficiency is 50% and specific 
for a particular donor-acceptor pair, is defined as:  
                                
                                R0=(Jκ2Q0n-1)1/6*9.7*103                Eq.2 
The value of Ro depends on J, the spectral overlap integral; κ2, the orientation 
factor for a dipole-dipole interaction; n,  the refractive index of the medium between the 
donor and acceptor; and Qo, the quantum yield of fluorescence of the energy donor in the 
absence of acceptor. The value of κ 2 cannot be directly measured and is the major 
uncertainty in the calculation of distance. Its value depends on the relative orientations of 
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the donor and acceptor dipoles; it is 0 if all angles are perpendicular and 4 if both 
transition moments are in line with the separation vector. Provided that both donor and 
acceptor can undergo unrestricted isotropic motion and rotate freely, κ2 assumes a 
numerical value of 2/3. Dos Remedios and Moens (1995) argued that the assumption of a 
value of 2/3 for κ 2 appears to be valid for small peptides and small proteins. The CFP 
and YFP should have considerable motional freedom as they are attached to the rest of 
the peptide molecule via covalent single bonds. Assuming κ 2 = 2/3 and Ro=50 Å for the 
CFP and YFP pair (Patterson et al., 2001); these values were used in the calculation of 
distances.  
As the presence of an energy acceptor in the vicinity of an excited energy donor 
provides an additional mode for the deexcitation process, from donor quenching, E is 
calculated from the equation:  
                                   E=1-IDA/ID                Eq 3. 
where IDA is the fluorescence intensity of the donor in the presence of acceptor and ID is 
the fluorescence intensity of the donor only. 
Protein crystallization  
Protein concentration was measure by its absorbance at 280 nm. Fv and Sumo-
Q10P10 were mixed at a 1:1 molar ratio and concentrated to 15 mg/mL with Amicon 
Minipore. Protein sample was centrifuged at 15,000 rpm for 5 min at 4°C to remove 
aggregate before setting up hanging drop crystallization.  About 200 crystal growing 
conditions were screened including Crystal Screen I & II and Index kit (Hampton 
Research, CA). Each microplate well was filled with 0.5 ml crystal growing solution. 
Then 2 ul of reservoir buffer was mixed with 2ul of protein sample on the center of 
coverslip. The well was sealed with grease to allow diffusion between hanging drop and 
mother liquid. (See Figure 13) 
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FIGURE 13. Protein crystallization by hanging drop. 
 
 
Fv-Q10P10 structure determination 
Further crystallographic studies were conducted with the MW1 Fv/Q10P10, 
which was crystallized in 50 mM Tris, 2.0 M (NH4)2SO4 at pH 8.5. by the hanging drop 
vapor diffusion method. Crystals (space group P21 with two Fv molecules in the 
asymmetric unit) were cryo-preserved in liquid nitrogen in mother liquor containing 
30% glycerol. Diffraction data from a single crystal were collected at -150 °C at 
beamline 8.2.2 (wavelength = 0.9537 Å) using a Quantum CCD detector at the 
Advanced Light Source (ALS, Berkeley). (The Advanced Light Source is supported by 
the Director, Office of Science, Office of Basic Energy Sciences, Materials Sciences 
Division, of the U.S. Department of Energy under Contract No. DE-AC03-76SF00098 at 
Lawrence Berkeley National Laboratory.) The data were processed with Denzo and 
Scalepack as implemented in the HKL2000 suite. The structure was determined by 
molecular replacement with MOLREP in the CCP4 suite using the search model of the 
Fv. Model building was done using O. The structure was refined using individual B 
factors and CNS. NCS restraints were not applied during the refinement since the two Fv 
molecules in the asymmetric unit had different packing environments.  
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Results 
Spectral overlap between CFP and YFP 
The most popular FRET pair for biological use is cyan fluorescent protein (CFP)-
yellow fluorescent protein (YFP). Both are color variants of the green fluorescent protein. 
CFP and YFP can be easily attached to the host protein by molecular cloning. CFP-YFP 
pair saves the troublesome processes of chemical modification of organic fluorescent 
dyes. For FRET to occur, the emission spectrum of the donor probe must overlap 
considerably the absorption spectrum of the acceptor probe (Figure 14).  
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FIGURE 14. Spectral overlap of CFP and YFP. The corrected emission spectrum of 200 
nM CFP (blue) and the absorbance spectrum of the 10 nM YFP (red) in Tris-HCl buffer. 
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Normal and expanded polyQ tracts adopt the same extended structure in solution. 
Huntington Disease severity and the early onset are closely related to the length 
of the polyQ tract in the first exon of huntingtin gene. It is wide accepted that the 
expanded polyQ tract (>36) adopts a different conformation from the normal polyQ tract 
(8-35), which gives rise to the formation of a β-sheet structure and later on a nucleation 
process. However, our previous SPR binding experiments indicate that the antibody 
MW1 binds specifically with both the normal and expanded polyQ tracts. It was 
suggested that normal and expanded polyQ tracts adopt the same extended structure in 
solution. 
To study the conformation of polyQ tract, we linked CFP and YFP together by 
peptides of n polyglutamine residues (n=10, 20, 37, 46). (See Figure 15A) If the CFP 
and YFP are close enough to each other, excitation of CFP moiety will result in the 
sensitized emission from the YFP moiety as a consequence of resonance energy transfer 
(Miyawaki and Tsien, 2000；Tsien, 1998). If the polyQ tracts adopt the same extended 
structure regardless of the number of glutamine residues, we expected to see a decrease 
in FRET efficiency with the increasing number of glutamine residues.  
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FIGURE 15. CFP-Qn-YFP fusion proteins. (A) Schematic representation of the CFP-
Qn-YFP constructs. CFP and YFP were connected via a polyglutamine peptide.  (B) 
Purified CFP-Qn-YFP fusion proteins on SDS-PAGE. 
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We measured the emission spectra of CFP-Qn-YFPs from 450-600 nm by 
PerkinElmer LS55 fluorometer. The excitation wavelength is 434 nm. The protein 
concentration is 300 nM in Tris-HCl buffer, pH 7.5. This concentration was chosen, 
because it is high enough to give fluorescence signal against the background while it is 
diluted enough to prevent the potential aggregation of polyQ tracts.  There are two major 
peaks in the emission spectrum. One is CFP peak at 476 nm, the other one is YFP peak 
at 527 nm. All four CFP-Qn-YFP constructs can yield FRET signals (Figure 16). The 
CFP peak decreases while YFP peak increases correspondingly. CFP-Q10-YFP fusion 
protein has FRET efficiency of 37.9%. CFP-Q20-YFP fusion protein has a lower FRET 
efficiency of 27%. CFP-Q37-YFP and CFP-Q46-YFP fusion protein, which are above 
the threshold of normal polyQ tract in HD exon1, have FRET efficiency of 9.0% and 
8.5%. Taking all the spectra into account, we suggested that the distance between N-
terminal and C-terminal of polyQ tracts are determined by the number of glutamine 
residues. The data support the linear lattice model proposed by Bennett et al.. in 2002, in 
which HD exon1 fusion proteins with 16 to 46 glutamine residues reveal the same 
extended structures with random coil characteristics. FRET results reveal no global 
conformational change above 36 glutamines. FRET spectra excludes the possibility that 
expanded polyQ adopts the β-sheet model and bring the two ends of polyQ together to 
yield FRET signal.  
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FIGURE 16. CFP-Qn-YFPs yield FRET signal in vitro. His6-tag-CFP-Qn-YFP (300nM) 
was selectively excited at 434nm, which is optimal for CFP. The scan emission spectra 
(450 nm-600 nm) are shown. The left arrow indicates the CFP emission peak, the right 
arrow indicates the YFP emission peak. The emission spectra of CFP and YFP alone, as 
well as the 1:1 mixture of CFP and YFP, are also included. These control spectra 
indicate that YFP yields a slight emission signal when directly excited at 434 nm, and 
FRET does not occur unless CFP and YFP are linked together.  
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The FRET distances were also calculated based on Eq. 2, assuming R0 is 50 Å 
(Table 1). CFP emission intensity with and without YFP at 476 nm (Ex 434 nm) were 
obtained from duplicate measurements. Q10P10 peptide is about 63 Å in the solution by 
FRET experiment. It agrees with the X-ray crystallography results, in which Q10P10 
bound to Fv is about 52 Å.   
We also inserted HD exon1 containing different lengths of polyglutamine (16, 25, 
37, and 46) between CFP-YFP fusion proteins. The distance between the N-terminus and 
C-terminus of HD exon 1 is too far (>100 Å) from each other to yield significant 
FRET signal (Figure 17).   
 
 
Table 1. Distance of polyQ tracts determined by FRET  
  Linker 
sequence 
FRET 
efficiency % 
R (Å) 
Q10 Q10KL 37.9 54 ± 0.5 
Q20 Q20KL 27.0 59 ±0.3 
Q10P10 Q10P10KL 18.9 63 ±0.6 
Q37 RDPQ37 KL 9.0 73 ±0.5 
Q46 RDPQ46 KL 8.5 76 ± 1 
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FIGURE 17. CFP-HD exon 1-Qn-YFPs do not yield FRET signal in vitro. The fusion 
proteins were excited at 434 nm and emission spectra were scanned from 450 nm to 600 
nm. The protein concentrations were in 100 nM in Tris-HCl buffer, pH 7.5.   
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MW1 Fv binds with polyQ tracts 
The interaction between MW1 antibody and polyQ was studies with SPR in 
context of TRX HD-exon1 fusion protein (Bennett et al., 2002). Genes encoding the 
MW1 VH and VL domains were isolated from the MW1 hybridoma. Noncovalent MW1 
Fv was refolded from denatured VH and VL expressed separately in E.coli. Fv and CFP-
Qn-YFP were mixed at a 1:1 ratio and analyzed by gel filtration column. Fv and CFP-
Qn-YFP alone were applied as control as well. The elution volume of Fv corresponds to 
an apparent molecular mass equals to 25kDa (Red curve).This is calculated based on the 
standard curve generated using protein of known molecular mass. The elution volumes 
of CFP-Qn-YFP (n=10, 20, 37, 46) are 13.95 ml, 13.84 ml, 13.54 ml and 13.21 ml 
respectively Black curve). After mixing CFP-Q10-YFP and Fv, the mixture shows no 
peak shift, which suggests no protein complex is formed (Green curve, Fig18A).  
However, the crystal structure shows that MW1 binds to short peptide epitopes of 10 Gln 
(Ko et al., 2001; Li et al., 2007).  One explanation is that CFP and YFP sequester some 
of the glutamine residues and less than 10 glutamines are exposed to the binding site of 
MW1 Fv. MW1 Fv and CFP-Qn-YFPs (when Q≥20) can form a protein complex, which 
is indicated by a elution volume peak shift to the left after mixing these two proteins 
(Figure 18 B-D green curve). At the meanwhile Fv peaks diminish correspondingly. 
These results implicate Fv can bind tightly with CFP-Qn-YFPs and form a stable protein 
complex when n>20.  
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FIGURE 18. Gel permeation chromatography of Fv and CFP-Qn-YFPs. Column: 
Superdex 200 analytical column (20 ml); sample volume: 100 ul; sample concentration: 
50 uM; flow rate: 0.5 ml/min; elution buffer: Tris-HCl, pH 7.5  (A) n=10, The 
absorbance profile at 280 nm shows two major peaks, 16.84 ml for Fv and 13.95 ml for 
CFP-Q10-YFP.  No peak shifts after combining Fv and CFP-Q10-YFP. (B)(C)(D) 
n=20,37,46. Fv peak diminishes and the first elution peak shifts to left, which is assumed 
to be Fv/CFP-Qn-YFP complex (green curve). 
 
 
 
 
CFP-Qn-YFPs tend to aggregate in high concentration  
The aggregation of CFP-Qn-YFP fusion protein was monitored by measuring the 
ratio of Em527/ Em476 with Perkin Elmer LS55. Emission spectra were first collected 
when the concentration of CFP-Qn-YFP equals 200 uM. Then a series of 2 fold dilution 
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was conducted, and emission spectra were scanned at each diluted concentration (Figure 
19). Each spectrum was read three times. The experiments were repeated three times 
independently. 
For all the four fusion protein, FRET efficiencies (implicated by Em 527/ Em 476) 
are apparently higher in higher protein concentration. When the concentrations decrease 
to about 10uM, the curves become flat. These results suggest that CFP-Qn-YFPs may 
adopt a different conformation in high concentration to bring the N-terminal CFP and C-
terminal YFP in close proximity. When the samples are diluted, the aggregations are 
reversed. Then the fusion proteins exit as monomer with extended polyglutamine tracts 
of random coils.  
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FIGURE 19. Concentration dependence of FRET efficiency. CFP-Qn-YFPs were 
excited at 434 nm. Emission intensity was measured at 476 nm and at 527 nm 
respectively. Protein concentrations were diluted consecutively from 200 uM to 400 nM.  
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MW1 breaks down the aggregated polyQ fusion protein and helps stabilize the 
protein in a more extended conformation  
MW1 Fv binds the polyQ tract with a weak binding affinity (Kd =3 μM). The 
concentrations of CFP-Qn-YFPs remain constant at 25 μM, and they were titrated with 
Fv of the increasing concentrations from 25 μM to 50 μM, 75 μM, 100 μM, 125 μM and 
150 μM. The ratio of Em527/Em476 was obtained as mentioned above. Em527/Em476 is 
2.18 for CFP-Q10-YFP at 25 μM. After mixing with 25 uM Fv, Em527/Em476 reduced to 
1.54. This observation implicated that Fv may interact with CFP-Q10-YFP and disrupt 
its β-sheet structure that exists in high protein concentration. The binding between CFP-
Q10-YFP and Fv is too weak to be observed on size exclusion column (Figure 20). CFP-
Q10-YFP is totally saturated with Fv if mixing them with a 3:1 ratio. The FRET signal 
does not decrease further even the ratio increases to 4:1, 5:1 and 6:1. CFP-Q20-YFP 
shows the similar binding curve as CFP-Q10-YFP. CFP-Q37-YFP and CFP-Q46-YFP 
show the similar emission spectra. These two proteins are not saturated with Fv until the 
ratio reaches 5:1. These results suggest that CFP-Q37-YFP and CFP-Q46-YFP have 
more binding sites for Fv than CFP-Q10-YFP and CFP-Q20-YFP. This finding is 
consistent with the previous analytical ultracentrifugation experiments. AUC 
experiments show HD-exon1-46Q can bind multiple copies of MW1 Fv. (See Figure 21) 
The majority of HD-exon1-46Q bind with one Fv molecule in a 1:1 mixture (Blue curve). 
HD-exon1-46Q molecule binds two Fv molecules in a 1:2 mixture. HD-exon1-46Q is 
saturated with Fv in a 1:4 mixture, with four Fv molecules bound to each HD-exon1-
46Q.  
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 FIGURE 20. FRET spectra of CFP-Qn-YFPs with Fv titration.  
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FIGURE 21. AUC experiment of HD-exon 1 and Fv. Plot of the distribution of 
sedimentation coefficients c(s) versus sedimentation coefficients, s. Sedimentation 
coefficients are plotted in Svedberg units and calculated from the concentration profiles 
using SEDFIT.  
 
 
 
 
Crystallization of Fv/Q10P10 complex and structure determination 
We expressed SUMO fusion proteins of a peptide containing 10 glutamines and 
10 prolines (Q10P10). Fv/Q10P10 complex was generated by cleaving the SUMO tag 
with SUMO protease and purified with Ni2+ affinity column. The Fv-Q10P10 complex 
was crystallized in 50 mM Tris, 2.0 M (NH4)2SO4 at pH 8.5 (Figure 22A). The complex 
crystallized in P21 space group with unit cell parameters: a=50.38 Å, b=80.37 Å, 
c=286.67 Å. We have collected diffraction data for the Fv/Q10P10 complex crystals at 
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beamline 8.2.2 at ALS. The crystal diffracted to 3.5 Å at ALS using a Quantum 315 
CCD detector. The diffraction data were processed with the HKL-2000 package 
(Otwinowski and Minor, 1997). The structure was determined by molecular replacement 
using the program MOLREP (CCPN, 1994), with the Fv structure as search model. The 
molecular model of the peptides was built into the difference map using the program O 
(Jones and Kjeldgaard, 1997). The structure was refined with CNS (Brünger et al., 1998) 
to Rfree of 28.1 and Rwork of 24.6 (Table 2). 
 
 
Table 2. Data collection and refinement statistics for MW1 Fv/Q10P10 complex 
Data Collection 
Space group                                  P21 
Cell dimensions            
   a, b, c (Å)                                  50.38, 80.37, 286.67 
   α, β, γ ( º )                                 90.0, 90.32, 90.0 
Resolution (Å)                             50-3.15 (3.26-3.15)a  
Rmege                                          6.5(22.2) 
I/σI                                               22.9(4.9) 
Completeness ( % )                      90.5(67.2) 
Redundancy                                  3.0(3.0) 
 
Refinement 
Resolution (Å)                              50-3.15 
No. Reflections                             33904 
Rwork/Rfree                                      24.6/28.1 
No. atoms                                      
   Protein                                        10890 
   Peptide                                       451 
R.m.s deviations 
    Bond lengths (Å)                       0.014 
    Bond angles (º)                          1.90 
aValues in parentheses are for highest-resolution shell. 
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FIGURE 22. Structure of Q10P10 peptide bound to MW1 Fv. (A) Crystals of MW1 Fv/ 
Q10P10. (Each 10 division of the scale is 66um.) (B)Structure of Fv/Q10P10 complex, 
VL chain (green) and VH chain (light blue) are shown in ribbon diagram, while Q10P10 
peptide is shown in stick diagram. (C) Structure of Q10P10 peptide.   
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The Q10P10 peptide adopts an extended structure about 52 Å long and lies in the 
pre-existing diagonal groove of Fv. The overall structure of the Q10 region shows the 
same features as Q10 peptide in Fv/Q10 complex (Li et al., 2007). Residues Gln 2, 4, 8 
and 10 have the main chain dihedral angels of polyproline II helix. No hydrogen bonds 
were found between a glutamine side chain and the backbone carbonyl oxygen of the 
following residue, which is a characteristic of polyproline II helix. Gln5-7 form a short 
β-strand to interrupt the PPII helical structure. The P10 region does not bind with Fv 
molecule and sticks out to form a typical polyproline helical structure. The extended 
structure of polyproline is stabilized by crystal packing contact. The polyproline region 
does not seem to affect polyQ conformation as expected (Figure 22B, C). 
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CHAPTER III  
MOLECULAR MECHANISM OF TLR SIGNALING 
Objective 
Although the previous research study has given us a framework of proteins 
involved in TLRs signaling, the structure basis of protein-protein interaction is poorly 
understood. My primary goal is to study the molecular mechanism of TLR signaling 
using combination of structural and biochemical approaches.  
 
Specific aim 1: Elucidate the mechanism of MyD88 recruitment to TLRs 
MyD88 mediate TLRs signaling through homotypic interaction with TLR TIR 
domain. TLR TIR domains have average 30% sequence identity and the conserved core 
structure, but their surface structures have variance. There are two possible explanations 
for how MyD88 acts as a universal adaptor: 1) MyD88 interacts with TLRs by a 
conserved motif shared between different TLRs. 2) MyD88 interacts with TLRs with 
different interfaces. To investigate this problem, the most direct way is to obtain MyD88 
TIR and TLRs TIR complex and compare the structure to find out the answer.  
 
Specific aim 2: Indentify residues involved in MyD88 death domain and IRAK4 
death domain interaction 
There are two steps for forming the platform. 1) MyD88 oligomerization 2) 
MyD88 recruits IRAK4/IRAK1 via DD/DD interaction. We are interested in residues 
involved in both MyD88 oligomerization and DD/DD interaction motif.  
 
Specific aim 3: Investigate the mechanism of IRAK1 ubiquitination by Pellino1 
We previously determined the structure of Pellino1 and found its unique two 
RING-finger motif. A crystal complex of Pellino1/Ubc13/Uev1a or Pellino1/UbcH3 will 
help us to understand the different mechanism, by which Pellino1 catalyzes 
polyubiquitin chain linkage.  
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Experimental Procedures 
Construction of expression vectors 
MyD88, Pellino1, Ubc13 and Uev1a cDNA were purchased from Open 
Biosystem. Pellino1 baculovirus was generated by Xiaojun Li. pGEX-IRAK4DD and 
pBAC-TLR5-TIR were generated by Dr. Pingwei Li. DNA primers were ordered from 
Integrated DNA Technologies (Table 3). Primers were dissolved in ddH2O to make a 
final concentration of 1 mg/ml. MyD88 DD (19-136) was inserted between NdeI and 
SalI site of pET28. Pellino1 was inserted between BamHI site and XhoI site of pBAC. 
Ubc13 and Uev1a were inserted between NdeI and XhoI site of pET28.  Plasmids were 
transformed into DH5α cell. All the expression vectors were confirmed by DNA 
sequencing. (LPGT, Texas A&M)   
 
Table 3. Oligonucleotides used for construction of expression vectors 
Expression vectors  Sense primers  Anti-sense primers  
pET28 MyD88 DD (19-136) 5' tatatatacatatgtcccttcccctggctgctctc 3' 5' tatatagtcgacttagctgtctacagcggccacctg 3' 
pET28 Ubc 13 (1-152) 5' tatatatacatatggccgggctgccccgcagg 3' 5' tatatagtcgacttaaataataatcatggcatatag 3' 
pET28 Uev1a (8-147) 5' tatatatacatatgggagtaaaagtccctcgc 3' 5' tatatagtcgacttaattgctgtaacactgtcc 3' 
pET28 UbcH3 (7-184) 5' tatatatacatatgcccagctcgcagcag 3'  5' tatatagtcgactcagggcaccttcacgccgtc 3'  
pBAC MyD88  5' tatatagaattcatggctgcaggaggtcccggc 3' 5' tatatactcgaggggcagggacaaggccttggcaag 3'  
pBAC MyD88 TIR  5' tatatagaattcatgcctgagcgtttcgatgccttc 3'  5' tatatactcgaggggcagggacaaggccttggcaag 3'  
pBAC TLR3 TIR (748-904) 5' tatatagaattcatggacagacagacagaacagtttg 3' 5' tatatactcgagatgtacagagtttttggatcc 3'  
pBAC TLR4 TIR 5' tatatagaattcatgggtagaggtgaaaacatc 3'  5' tatatactcgaggatagatgttgcttcctgcc 3'  
pBAC TLR9 TIR (862-1032) 5' tatatagaattcatggggcgagatgaggatgccctg 3' 5' tatatactcgagttcggccgtgggtccctggcag 3' 
pBAC TIRAP TIR (79-221) 5' tatataggattcatgagtagtcgctggagcaaagac 3'  5' tatatactcgagactgagtgtctgcagataacgc 3'  
pBAC TRIF TIR (380-600) 5' tatatagaattcatgtccacatcccctgttttggac 3'  5' tatatactcgagccccagtgacaagttcttccc 3'  
 
 
Site directed mutagenesis 
Primers were dissolved with ddH2O to a final concentration of 125 ng/ul (Table 
4). Mutagenesis PCR reaction was mixed as follows: 50 ng DNA template, 1ul each 
primers, 5 ul of 10x reaction buffer, 1 ul of dNTP mixture, 1 ul of Pfu Ultra DNA 
polymerase (2.5 U/ul), ddH2O to a final volume of 50 ul. The thermal cycles are as 
follows: preheating to 95°C for 2 min, then 16 cycles of denaturing at 95°C for 30 sec, 
annealing at 55°C for 30 sec and elongation at 68 °C for 1 min, followed by cooling at 
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4°C. 1 ul of Dpn I restriction enzyme was added directly to PCR products and incubated 
for 2 hrs at 37°C to digest the parental DNA.  1 ul of Dpn I-treated DNA was added to 
60 ul XL1-Blue supercompetent cells, heat shock for 45 sec at 42°C and then place the 
reactions on ice for 2 mins. 0.5 ml of SOC media was added to the transformation 
reactions at 37°C for 1 hour with shaking at 250 rpm. 100 ul of cells were spread on agar 
plate and incubated overnight at 37°C. Colonies were picked and plasmids were 
prepared by Miniprep and sent for sequencing.  
 
Table 4. Primers used for site directed mutagenesis 
mutation sense primers antisense primers 
R40S 5’CTGTTCTTGAACGTGAGCACACAGGTGGCG3’ 5'CGCCACCTGTGTGCTCACGTTCAAGAACAG3' 
R62S 5'GTGTCTCCAGTTGGCTGATCTCCAAGTACTC3' 5'GAGTACTTGGAGATCAGCCAACTGGAGACAC3' 
R81S 5'GACGCCTGGCAGGGAAGCCCTGGCGCCTCTG3' 5'CAGAGGCGCCAGGGCTTCCCTGCCAGGCGTC3' 
R88S 5'GCCTCTGTAGGCAGCCTGCTCGAGCTGCTTAC3' 5'GTAAGCAGCTCGAGCAGGCTGCCTACAGAGGC3' 
R98S 5'CTTACCAAGCTGGGCAGCGACGACGTGCTGC3' 5'GCAGCACGTCGTCGCTGCCCAGCTTGGTAAG3' 
E52Q,R62S 5'CTCAAAGTCCATCTCCTGCGCCAGCGCGGTC3' 5'GACCGCGCTGGCGCAGGAGATGGACTTTGAG3' 
E53Q,R62S 5'CGCGCTGGCGGAGCAGATGGACTTTGAGATC3' 5'GATCTCAAAGTCCATCTGCTCCGCCAGCGCG3' 
D55N,R62S 5'CTGGCGGAGGAGATGAACTTTGAGTACTTGGAG3' 5'CTCCAAGTACTCAAAGTTCATCTCCTCCGCCAG3' 
E57Q,R62S 5'GAGGAGATGGACTTTCAGTACTTGGAGATCAGC3' 5'GCTGATCTCCAAGTACTGAAAGTCCATCTCCTC3' 
E60Q,R62S 5'GACTTTGAGTACTTGCAGATCAGCCAACTGGAG3' 5'CTCCAGTTGGCTGATCTGCAAGTACTCAAAGTC3' 
R62S,E65Q 5'GAGATCAGCCAACTGCAGACACAAGCGGACC3'  5'GGTCCGCTTGTGTCTGCAGTTGGCTGATCTC3'  
R62S,D69N 5'CTGGAGACACAAGCGAACCCCACTGGCAGG3'  5'CCTGCCAGTGGGGTTCGCTTGTGTCTCCAG3'  
 
 
Sf9 cell culture and transfection 
pBAC vectors were heat shock in water bath of 65 °C for 15 min. 4 x 106 Sf9 
cells in 5 ml volume were seeded in one T25 flask and placed in 27 °C incubator for 30 
min for cell attachment. Transfection mixture were prepared as followings: 200 ul 
Grace’s media , 2 ul BaculoGold TM DNA (BD Pharmingen), 5 ul Insect GeneJuice 
Transfection Reagent and 20 ug pBAC vector. Old Media were taken out and replaced 
with 4 ml Grace’s media after cell attachment to T25 flask. Transfection mixture was 
added to Sf9 cell and mixed well by rocking the flask back and forward. Sf9 cells were 
incubated at 27°C for 14-16 hrs. Grace’s media were replaced with 4 ml fresh HyQ-SFX 
media, and incubated for 4-5 days.  Cell culture was centrifuged at 4000 rpm for 5 min. 
Supernatant was stored with 0.5 ml FBS as P1 virus.  
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Baculovirus amplification  
107 Sf9 cells were seeded in T75 tissue culture flask in a total volume of 14 ml 
HyQ-SFX media. 2 ml P1 virus was added and placed in 27°C incubator for 5 days.  Cell 
media were harvested and saved as P2 virus with 1.5 ml FBS supplement. 2.5 x 106/ml x 
500 ml Sf9 cells were seeded in each 2L flask. 8-10 ml P2 virus were added and stirred 
at 100-120 rpm in 27°C incubator for 4 days. Supernatant was collected by spinning at 
4000 rpm for 5 min and stored as P3 virus with 10% FBS.  
 
Protein large scale expression and protein purification 
2.5x 106/ml x 500 ml Sf9 cells were seeded in each 2 L flask. 40-60 ml of P3 
virus was added and stirred at 100-120 rpm in 27 °C incubator. Cells were harvested 
after 2-3 days at 2000 rpm for 5 min. Cell pellets were dissolved in 50 ml lysis buffer 
(10% NP40, 0.2 M Tris-HCl, 0.15 M NaCl, pH 8.0). Cell lysate was gently mixed for 1 
hr at 4°C and spinned down at 16,000 rpm for 30 min. Supernatant was added with 5 ml 
Ni-NTA beads and mixed at 4°C for 2 hr. Ni-NTA beads were spinned down at 4000 
rpm for 1 min and washed with wash buffer for 3 times (10 mM imidazole，20 mM 
Tirs-HCl, 150 mM NaCl, pH 8.0). Protein was eluted with 10 ml elution buffer (0.25 M 
imidazole, 20 mM Tris-HCl, 150 mM NaCl, pH 8.0). 5 mM DTT and protease inhibitor 
was added to the eluted protein and stored at 4°C.  
 
Preparation of 15N MyD88DD (E52QR62S) for HSQC 
BL21 cells containing pET28 MyD88DD (E52QR62S) was inoculated to 2 x 1L 
Minimal Media (Tables 5, 6, 7).  Proteins were expressed and purified as described 
above. Protein solution (pH 6.5) is added to Shigemi NMR tube by pipetting slowly with 
a standard pipetter. If the sample becomes trapped by an air bubble before it reaches the 
bottom, stop adding sample and gently shake the tube to use centrifugal force to get the 
sample to the bottom. The plunger was inserted until it reaches the top of the sample. To 
remove air bubbles, rest the bottom of the tube on a table or other firm surface and 
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gently tap the plunger to force liquid and air around the plug. The top of the tube was 
sealed with parafilm and sent to Biomolecular NMR Lab, Texas A&M.  
 
Table 5. Minimal media 
 Amount (ml) Notes 
10x Minimal Salts 100   
Trace Elements 5   
MgCl2 5  1.0 M (autoclaved) 
Thiamine 2  20 mg/ml, sterile filtered 
Kanamycin 2  100 mg/ml, sterile filtered 
Glucose 40  20%, autoclaved 
H2O  850  
 
 
 
Table 6. 10x Minimal salts 
Compound Amount (g/100 ml) Notes 
KH2PO4 13.0 Adjust to pH 7.2–7.4 with KOH. pH should be 
about 6.7 before adjustment  
Autoclave 
K2HPO4·3H2O 13.1 (10.0 g anhydrous) 
Na2HPO4 9.0 
K2SO4 2.4 
15NH4Cl 1.1 
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Table 7. Trace elements 
Compound Amount (g/100 ml) Instructions 
EDTA-Na2 0.50 
Add the EDTA to a fraction of the water. 
Add each ingredient separately with 
stirring and wait several minutes. Add the 
rest of the water, wrap the container in foil 
and stir overnight. The color should turn 
from green to gold.  
Sterile filter 
CaCl2·2H2O 0.60 
FeSO4·7H2O 0.60 
MnCl2·4H2O 0.115 
CoCl2·6H2O 0.08 
ZnSO4·7H2O 0.07 
CuCl2·2H2O 0.03 
H3BO3 0.002 
(NH4)6Mo7O24·4H2O 0.025 
 
 
GST-tag pull down 
GST-IRAK4DD fusion protein and MyD88DD were immobilized on Glutathione 
Sepharose 4 Fast Flow (GE Healthcare, AB) by incubating the purified GST-IRAK4DD 
with beads at 4 °C nutation for 1 hr. The beads were washed 3 times with PBS buffer 
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) by 
centrifugation at 500g for 5 min. The bound protein was eluted by adding  0.5 ml 50 mM 
Tris-HCl, 10 mM reduced glutathione, pH 8.0 per 1 ml slurry of Glutathione Sepharose 
4 Fast Flow.  
 
Polyubiquitination assay  
A mixture of 0.1 uM E1, 1 uM Ubc13-Uev1a,  1 uM Pellino1, 0.1 mM ubiquitin, 
5 mM MgCl2, 2 mM ATP and with or without 1 uM GST-IRAK1 was incubated for 1 hr 
at 37°C in a total volume of 50 ul Tris-HCl buffer, pH 7.5. The reaction was terminated 
by the addition of SDS and resolved by SDS-PAGE.   
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Results 
Protein expression of TIR domains 
Our study on TIR-TIR domain interaction is hindered by the poor solubility and 
stability of TIR domains. The expression of TIR domains of TLR1, TLR2, TLR3, TLR4, 
TLR5 and TLR9 were tried in both E.coli and Sf9 cells. Sf9 cells can yield a small 
amount of TLR4-TIR (<1 mg/L) (Figure 23). After Ni-NTA beads purification, the 
purified TIR domain proteins were shown on SDS-PAGE. When the TIR domain 
proteins were loaded on the size exclusion column, the elution profile did not show a 
sharp single elution peak. It is because these TIR domain proteins tend to aggregate 
during the protein purification process.  TIR domain of the three adapter proteins: 
MyD88, TIRAP and TRIF were also expressed in both E.coli and Sf9 cells. The soluble 
proteins of TIRAP-TIR and MyD88 (E52QR62S) can be produced in pBAC vector in 
Sf9 cells (Figure 24). These proteins are stable only in low concentration (<2mg/ml). 
Alternative strategies like co-transformation, co-infection or adding GST-tag were 
applied to improve the protein stability and solubility, but little progress was achieved.  
 
 
FIGURE 23. SDS-PAGE of TLR1 (A), TLR2 (B), and TLR4 (C) TIR domains. 
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FIGURE 24. SDS-PAGE of full length human MyD88 (A) and GST-TIRAP TIR 
domain (B). 
 
 
 
Protein expression of IRAK4DD and MyD88DD in E.coli 
IRAK4DD was inserted to pGEX vector with GST-tag at the N-terminal as 
described (Lasker et al., 2005). MyD88DD was inserted into pET28 vector with N-
terminal His-tag. Both protein express vectors were transformed into BL21 and induced 
at 15°C for 14-16 hours. Both proteins were purified with either GST-tag or His-tag 
affinity chromatography, followed by size exclusion chromatography. Both proteins 
have a decent protein yield (~20 mg/L) (Figure 25). GST-tag and His-tag were cleaved 
off with thrombin and remove by size exclusion column. IRAK4DD is stable in Tris-
HCl buffer, pH 7.5, but MyD88DD tends to oligomerize under the same condition. 
Monodispersed MyD88 death domain is needed for the study of IRAK4 death domain 
and MyD88 death domain interaction.  
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MyD88DD
 
FIGURE 25. SDS-PAGE of IRAK4 death domain and MyD88 death domain.  
 
 
 
E52QR62S disrupts MyD88DD oligomerization 
 MyD88DD oligomerization cannot be disrupted by extreme pH or high salt 
concentration. MyD88DD sequence alignment and the secondary structure prediction 
were conducted. Eight residues were randomly selected on the conserved charge regions 
for site mutagenesis to neutralize the positive charge (Figure 26A). These mutants were 
expressed, purified and analyzed with size exclusion column.   A crucial mutant, R62S 
for MyD88DD oligomerization was identified. The mutation of Arg62 to serine on helix 
2 disrupts MyD88DD oligomerization and stabilizes it in dimeric form. Other mutations 
had little effect on MyD88DD oligomerization (Figure 26B). 
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FIGURE 26. Site mutagenesis of MyD88 death domain. (A) Sequence alignment of 
MyD88. The mutation sites are indicated by red arrow. (B) Gel permeation 
chromatography of four soluble MyD88 death domain mutants. R62S is represented by 
green curve.  
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For crystallization, protein concentration must reach a critical value (usually > 10 
mg/ml). Although the single R62S mutant is stable in a low concentration (~ 2mg), it 
aggregates during the concentration process. Thus, seven double-mutants on helix 2 
were screened and compared on the gel permeation chromatography. E52QR62S has the 
sharpest elution peak among all (Figure 27).  This double-mutant MyD88DD is 
monodispersed in high concentration (~15 mg/ml). Therefore, it could be a good 
candidate for protein crystallization and NMR experiments.  
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FIGURE 27. Site mutagenesis of helix 2 in MyD88 death domain. (A) Sequence 
alignment of MyD88 helix 2. The mutation sites of negative charge are indicated by 
green arrow. (B) Gel permeation chromatography of seven soluble MyD88DD double-
mutants. E52QR62S is represented by green curve.  
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GST pull down of MyD88DD (E52QR62S) and IRAK4DD 
MyD88DD can interact with IRAK4DD and activate the down stream of TLR 
signal pathway. To make sure that the MyD88DD (E52QR62S) retains the function as 
the wild type MyD88, GST-pull down experiments were conducted to test the binding 
between MyD88DD (E52QR62S) and IRAK4DD. GST-IRAK4DD and MyD88DD 
(E52QR62S) were expressed in E.coli as describe above. GST-IRAK4DD and 
MyD88DD (E52QR62S) were mixed at a 1:1 molar ratio and incubated with Glutathione 
Sepharose beads for 2 hours. The beads were washed with PBS buffer for 3 times and 
eluted with 50 mM reduced glutathione. MyD88DD (E52QR62S) can bind with 
IRAK4DD and comes out in the elution buffer with GST-IRAK4DD (Figure 28). The 
same procedures were carried out with only GST-IRAK4DD or MyD88DD as control.   
 
 
 
1           2          3         4          5           6
GST-IRAK4DD - +      +     - +      +          
MyD88DD +      - +     +      - +
GST-IRAK4DD
MyD88DD
Input                      Elution 
 
FIGURE 28. GST pull down of IRAK4 death domain and MyD88 death domain. 
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FIGURE 29. 2D 1H-15N HSQC of MyD88DD (E52QR62S). (1 mM in Tris-HCl buffer, 
pH 6.5) The experiments were carried out by Biomolecular NMR Lab, Texas A&M.  
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HSQC of MyD88DD (E52QR62S) 
The crystallization trial of MyD88DD (E52QR62S) was carried out with 300 
crystallization conditions, but none of them yielded a crystal. NMR spectroscopy was 
applied to solve the structure of this protein as an alternative method, since MyD88DD 
(E52QR62S) is within the range of NMR study (~17KDa). 15N HSQC experiment is 
probably the most frequently recorded experiment in protein NMR spectroscopy. Each 
residue of the protein (except proline) has an amide proton attached to a nitrogen in the 
peptide bond. Each N-H group gives an individual cross peak because of the different 
environments.  If the protein is folded, the peaks are usually well dispersed, and most of 
the individual peaks can be distinguished. The number of peaks in the spectrum should 
match the number of residues in the protein plus the sidechains with nitrogen-bound 
protons, like argine and lysine. H1 -15N cross peak are well disperse and each one 
represent on N-H group (Figure 29). Thearetically there are 131 N-H groups in the 
protein. On the HSQC spectrum, there are about 120 individual peaks. It sounds a good 
alternative method to solve the structure by NMR spectroscopy based on this 
preliminary HSQC spectrum.    
 
Expression of Pellino1 and Ubc13/Uev1a 
Ubc13 and Uev1a were expressed in pET28 vector and purified as described 
(Zhang et al., 2005). Pellino1 was inserted in pBAC vector and expressed in Sf9 insect 
cells. All three proteins were first purified by His-tag affinity column and followed by 
Superdex sizing column. The purified proteins were loaded on SDS-PAGE to check 
purity. A clear single band of SDS-PAGE (Figure 30) and a single peak on gel 
permeation chromatography (data not shown) indicate that the proteins are pure enough 
for protein crystallography.  
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FIGURE 30. SDS-PAGE of Pellino1, Ubc13 and Uev1a.  
             
                          
Pellino1 (E3) induces the formation of pUb chains in the presence of Ubc13/Uev1a 
(E2) 
The human genome is thought to encode one E1 enzyme, 50 E2 conjugating 
complexes and over 500 ubiquitin E3 ligases. It is like a pyramid structure. Each E2 
conjugating complex must operate with 10-20 E3 ligases. E3 ligases are responsible for 
the substrate specificity. In the previous study, Pellino1 was able to catalyze the 
formation of polyubiquitin in conjunction with five E2 complexes in vitro (Ordureau A 
et al., 2008). In the presence of Ubc13/Uev1a and active IRAK1, Pellino1 induces the 
formation of pUb chains (Figure 31, lane 4). A catalytical inactive mutant of IRAK1 
greatly decrease its ligase function (Figure 31, lane 3). Taking together, wild type 
IRAK1 phosphorylates Pellino1 and enhances its E3 ligase activity. The main purpose of 
this assay is to make sure that the proteins used for crystallization are properly folded 
and retain its function.  
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FIGURE 31. IRAK1 phosphorylates Pellino1 and enhances its E3 ligase activity. A 
mixture of 0.1 uM E1, 2 uM Ubc13-Uev1a, 5 uM Pellino1, 0.5 mM ubiquitin, 5 mM 
MgCl2, 1 uM IRAK1 (inactive or active) and without ATP (lane 1) or with ATP (lane 
2,3) in 50 mM Tris-HCl buffer pH 7.5 was incubated for 2 hours at 37 °C in a total 
volume of 50 ul. The reaction was stopped by the addition of SDS and the samples were 
loaded on SDS-PAGE and visualized by Coomassie Blue.  
 
 
Co-crystallization of Pellino1 and Ubc13/Uev1a 
Ubc13 and Uev1a were first mixed at a 1:1 ratio and the protein complex was 
isolated from free Ubc13 and Uev1a with Superdex 200 column. Then Ubc13/Uev1a 
complex was mixed with Pellino1 at 1:1 molar ratio. Since the binding between 
Ubc13/Uev1a and Pellino1 was weak, the complex of three proteins was not formed on 
Superdex 200 column. The mixture of three proteins was concentrated to 10 mg/ml. 
Protein crystallization was set up by hanging drop method with 200 conditions from 
Crystal Screen kit and Index kit (Hampton Research, CA). Needle clusters of protein 
crystal were found in the following two conditions: 0.1 M Na(CH3)2AsO2 ·3H2O，1.4 
M CH3COONa ·3H2O, pH 6.5 and 1.8 M NaH2PO4, K2HPO4, pH 5.0 (Figure 32). These 
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conditions were optimized to generate single crystals for data collection. However, the 
difficulties in crystallization protein complex prevent us from fully achieving the above 
goals. However, the progress describe in the thesis provide a foundation for future work.  
 
 
 
 
 
FIGURE 32. Crystals of Pellino1/Ubc13/Uev1a complex. (Each 10 divisions of the scale 
corresponds to 66 μm.) 
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CHAPTER IV 
CONCLUSIONS  
Polyglutamine Conformation 
In the first part of the thesis, we studied the polyglutamine conformation in pre-
aggregation stage using fluorescence resonance energy transfer.  We constructed a series 
of CFP-Qn-YFP fusion proteins. This simple system enabled us to assess conformational 
changes, oligomerization, and fibril formation. Our FRET data reveal that both the 
normal and pathologic polyglutamine adopt the same random coil extended structure in 
low concentration (300 nM). There was no global conformational change for polyQ 
tracts longer than 36 residues. FRET efficiency was determined by the number of 
glutamine residues in polyQ tract. Our experimental results also showed that FRET 
efficiency is concentration dependent.  When concentration increases, FRET efficiency 
increased accordingly. This finding suggests that polyQ may adopt a β-strand structure 
to bring CFP and YFP in close proximity. We proposed a “tug of war” model to combine 
the concentration dependent phenomenon and the linear model (Bennett, 2002): PolyQ 
peptide exits in a tug of war between two conformations:  a random coil and a β-sheet. 1) 
Irrespective of peptide length, polyQ tracts adopt a random coil structure in low 
concentration. 2) The longer polyQ tract has multiple cooperative binding sites that 
greatly enhance its binding affinity to the antibody. This aberrant binding affinity could 
be the reason of Huntingtin protein aggregation. 3) The formation of β-strand or β-sheet 
structure occurs when peptide concentration exceeds 10 uM. Once a critical 
concentration is reached, the polyQ tracts begin to nucleate and form aggregates. 4) Lag 
times and critical concentrations decrease with increasing chain lengths.   
We predict that FRET efficiencies of CFP-Qn-YFPs will greatly decrease upon 
the binding of antibody MW1 Fv. In this way, Fv can break apart the aggregates and 
stabilize polyQ tracts when they are in an extended conformation. This new information 
could be used to develop a therapeutic antibody for Huntington’s disease. Since the 
longer polyQ tracts contain multiple binding sites, the covalent linkage of Fv can 
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produce a new bivalent or multivalent compound with high avidity and specificity for 
pathologic soluble polyQ tracts. This approach would greatly reduce the potential 
disruption of other normal polyQ tract containing proteins.      
Besides the antibodies, trehalose is another compound used in preventing Htt 
aggregation. Trehalose is a natural disaccharide synthesized by fungi, plants and 
invertebrate animals. Trehalose interacts with the expanded polyglutamine tract of the 
proteins, stabilizing polyQ structure and inhibiting protein aggregation at the initial stage 
of aggregate formation (Tanaka et al., 2004). Based on Tanaka's work, trehalose is now a 
lead compound for cure in Huntington's disease patient and has potential for delaying 
onset or decreasing progression rate in this disease. In the future, it would be interesting 
to study the binding interaction of trehalose and polyQ tract using the existing CFP-Qn-
YFP system. We can also try to co-crystallize of trehalose and polyglutamine peptides.  
In addition, the flanking polyproline sequence has been shown by other groups to 
attenuate the cytotoxicity of polyQ tract in Saccharomyces cerevisiae. It is also 
suggested that the polyproline region may regulate Huntingtin protein conformation to 
influence its aggregation and subcellular localization (Qin et al., 2004). To examine the 
effect of the flanking polyproline sequence, we successfully crystallized Fv/Q10P10 
complex and determined the structure with molecular replacement with Fv as a search 
model. Compared the structure of Q10P10 peptide with Q10 peptides, the overall 
structure of polyQ tract shows the same features as Q10 bound to Fv: Gln 2, 4, 8, 10 
have the dihedral angels of a PPII like helix, while Gln 5-7 form a short β-strand to 
interrupt this PPII helical structure. Thus, the flanking polyproline does not confer 
structural stability to polyQ tract as expected. The polyproline region is conformational 
constraint into PPII helix. This finding agrees with circular dichroism spectroscopy data, 
in which polyproline peptide shows a PPII like helical structure (Darnell et al., 2007). 
An ideal PPII helix has backbone dihedral angles (φ,ψ) = (-75°, +145°), resulting in 
precisely three residues per turn. PPII helix is often observed in turns, most commonly in 
the first residue of a type II β-turn and also in unfolded proteins. PPII helices are 
specifically bound by the SH3 domain; this binding is important for many protein-
 63
protein interactions. The deletion of polyproline might affect Huntingtin structure and 
Huntingtin interaction with binding partners, like Grb2 and RasGAP in the Ras-
dependent signaling pathways (Liu et al., 1997).  
In summary, this study characterizes the structural features of soluble 
polyglutamine and polyproline peptides in the N-terminal of Huntingtin protein. Our 
finding provides useful information to elucidate pathologic mechanism of Huntington’s 
disease and contributes to antibody engineering for this disease.  
 
Toll-like Receptor Signaling Pathway 
The second part of this thesis focuses on the Toll-like receptor signaling pathway. 
Firstly, we wanted to study the recruitment of the adaptor protein- MyD88 to TLR 
through the TIR/TIR domain interaction. TIR domains of TLR1 and TLR2 show the 
same canonical structure: five β-strands form the core surrounded by five α-helices on 
both sides and five loops that connect between each β-strands and α-helices. It is 
interesting to study how MyD88 acts as a universal adaptor for most of the TLRs. We 
constructed TIR domain of MyD88 and TLRs, including TLR1, 2, 3, 4, 5, 7 and 9 in a 
pET28 vector and expressed the recombinant proteins in E.coli. Unfortunately, none of 
the recombinant proteins had good solubility and stability. We also constructed pBAC 
TIR domain expression vector and transfected Sf9 insect cells with baculovirus. 
Although this baculovirus-assisted insect cell expression system has the advantage of 
post-translational modification and proper protein folding, we were still unable to 
produce soluble TIR domain proteins. Co-infection of MyD88 TIR domain and TIRAP 
TIR domain into Sf9 cells did not improve protein yield and stability.  In the future, it 
should be possible to construct a fusion protein, with linker region connecting TLR1 or 
TLR2 TIR domain and MyD88 TIR domain to solve this problem. The adjacent TLR1 or 
TLR2 TIR domain should bind with MyD88 TIR domain and stabilize it in the TIR/TIR 
domain complex.  
The DD superfamily is one of the largest and most widely distributed domain 
superfamillies. DD superfamily inserts its domain into various signal transduction 
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proteins such as caspase, kinases, and adaptor proteins. MyD88 is the only adaptor that 
contains both the DD and TIR domain in the TLR signaling pathway. Site mutagenesis 
reveals that electrostatic interaction of helix 2 in death domain of MyD88 is responsible 
for self-assembly. Single mutation from Arginine 62 to Serine could break apart MyD88 
death domain oligomers.  Two mutations introduced into the MyD88 death domain 
(E52QR62S ) result in a monomeric form of the protein. Results from a GST-pull down 
experiment suggest that the double mutation does not affect the binding between 
MyD88DD and IRAK4DD. Far UV circular dichroism spectra indicate that the MyD88 
death domain mainly consists of α-helices. This is consistent with our secondary 
structure prediction, in which the MyD88 death domain is a six helices bundle.   
To study the interaction of MyD88 death domain and IRAK4 death domain, we 
set up protein crystallization with a 1:1 protein mixture. Several crystallization trials 
were conducted at different temperatures or with different crystallization solutions. Our 
attempt to crystallize MyD88DD/IRAK4DD complex failed for unknown reasons. An 
alternative approach to identify the residues involved in MyD88DD and IRAK4DD 
binding is NMR spectroscopy. The HSQC spectrum shows well dispersed cross peaks 
for the 15N-MyD88DD double mutant. This indicates that this protein is folded and could 
be a good candidate for structure determination by NMR. HNCACB and CBCACONH 
could be collected to assign the residues. Titration MyD88DD with IRAK4DD and 
mapping the chemical shift would help us to identify the residues on the binding 
interface.  
Beside MyD88DD and IRAK4DD interaction, MyD88DD oligomerization is 
also important for TLR signaling. The self-assembly of the death domain is a common 
feature in the death domain suprfamily. A recent publication shows the crystal structure 
of the oligomeric PIDDosme core complex comprised of seven RAIDD death domains 
and five PIDD death domains ( Park et al., 2007b). This complex uses an asymmetric 
assembly mechanism and has eight unique interfeaces. In the future it will be interesting 
to determine whether the MyD88 death domain forms similar platform to mediate TLR 
signaling. For this purpose, the MyD88 DD oligomer (> 600 kDa) by electron 
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microscopy to find out the packing pattern of the molecules. A crystallization trial for 
wild type MyD88 death domain can also be pursued.   
The ubiqiutin-protesome plays a crucial role in TLR signalling activation. 
Pellino1 is a newly identified E3 ubiquitin ligase. In vitro ubiquitination assays show 
that Pellino1 catalyzes K63-linkage ubiquitination on IRAK1 in the presence of 
Ubc13/Uev1a complex. Pellino1 contains two CHC2  RING motifs and each of them 
coordinates with one zinc atom. This tandom arrangement of two RING motifs are 
different from all other known E3 ligases.  To elucidate the mechanism of IRAK1 
ubiquitination, we expressed and purifed Pellino1, Ubc13 and Uev1a separately. These 
three proteins were mixed in a 1:1:1 ratio and used for protein crystallization. Needle-
cluster shape crystals were found in two conditions. These cystasl were harvested and 
verified by SDS-PAGE. We optimized crystallization conditions such as pH, precipitant 
concentration, temperature and protein concentration to generate single crystals. Thus far 
we have been unable to obtain the single crystals. Other approaches to optimize the 
crystallization conditions include the following: 1) Additives, which could stop 
nucleation and may give you fewer, larger crystals. 2) Oil, diffusion can be slowed down 
by adding a layer of oil on the top of hanging drop well. 3) Seeding, this is used to grow 
crystals of the same lattice and symmetry from an identical macromolecule. Once the 
conditions are optimized, X-ray diffraction data can be collected to determine the 
structure of Ubc13/Uev1a/Pellino1. The structural data accumulating on ubiquitination 
enzyme complexes are helping to fill in the pieces of the molecular jigsaw puzzles that 
comprise these protein modification systems. However, there are still very few examples 
of well-defined recognition motifs in E2/E3 complex within the ubiquitin system, and 
very little is known about E3 substrate specificity. This study begins to address these 
issues as well as the many other unresolved mechanistic questions about ubiquitination 
in the TLR signaling pathway.  
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